Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SEA-TGT + brentuximab vedotin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SEA-TGT + brentuximab vedotin is a combination immunotherapeutic regimen under investigation for the treatment of hematologic malignancies and possibly other cancers. **SEA-TGT** is a novel investigational T-cell engager (likely a therapeutic antibody designed to modify T-cell response), though specific details about its target and molecular structure are not publicly disclosed. **Brentuximab vedotin** is an anti-CD30 antibody-drug conjugate (ADC) that selectively targets CD30-positive tumor cells, internalizes, and releases the cytotoxic agent monomethyl auristatin E (MMAE) to induce cell cycle arrest and apoptosis. Brentuximab vedotin is approved for several CD30+ lymphomas including classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, usually as part of combination therapy[1][2][3][4][5][7].
- Other names
- SEA-TGT + brentuximab vedotin
02
Targets
CD30 (CD30 antigen)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on SEA-TGT + brentuximab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SEA-TGT + brentuximab vedotin.